Ayala Pharmaceuticals Inc (ADXS)

[blueyedcatch]

Adxs asking for the trial redesign is what triggered this,so I don`t agree that they`re separate issues. Adxs can`t fund the AIM2CERV as it stands,so continuing to enroll patients on a trial their asking the FDA to approve a redesign for, seems to be a logical outcome. Besides,asking to shorten the trial to reduce costs,and get an earlier data read,has to involve changing the dosage and times given. Look at it this way,we heard something back from the FDA,instead of sitting here not even knowing if Adxs was in communications with them regarding the AIM2CERV,so the balls in motion,and we`re closer to the redesign approval then yesterday.Besides I still say our next catalyst is Merck for PSA,,Axal,HOT,and maybe NEO. Cervix was last